Case Report

Intraventricular CNS aspergillosis in a patient with prior history of COVID-19: Case report and review of literature

Samuel Berchi Kankam a,d, Hiva Saffar b, Milad Shafizadeh a,d, Shirin Afhami c, Alireza Khoshnevisan a,d,*

a Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
b Department of Pathology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
c Department of Infectious Diseases, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
d International Neurosurgery Group (ING), Universal Scientific Education and Research Network (USERN), Tehran, Iran

ARTICLE INFO

Keywords:
CNS
Aspergillosis
COVID-19
Intraventricular space
SARS-CoV-2
Case report

ABSTRACT

Introduction and importance: Although some immunocompetent patients have developed invasive aspergillosis, the vast majority of cases are seen in immunocompromised patients. COVID-19 infection has been proposed to cause immune dysfunction or suppression, which predisposes patients to fungal co-infections such as mucormycosis and aspergillosis.

Case presentation: A 58-year-old woman was admitted to the hospital with confusion, dysarthria, and loss of consciousness. The patient had a 1-month prior history of severe COVID-19 infection. A computerized tomography (CT) scan and a magnetic resonance imaging (MRI) revealed an intraventricular lesion with perilesional edema and a significant midline shift, which was initially thought to be an intraventricular tumor. Following a posterior parietal craniotomy, the lesion was resected via a transcortical approach from the posterior parietal region to the right lateral ventricle. Histopathological findings confirmed intraventricular aspergillosis (IVA). The patient was treated with intravenous amphotericin B for two months and discharged with oral voriconazole for 4 months.

Discussion: Covid-19 infections can result in dissemination of fungal diseases such as aspergillosis. As a minor component of cerebral aspergillosis with a poor prognosis, intraventricular aspergillosis necessitates prompt treatment, which includes surgical resection and the administration of anti-fungal medications.

Conclusion: Infection with COVID-19 causes immune dysfunction, which leads to fungal co-infection, including CNS aspergillosis. As a result, all COVID-19 patients who present with acute neurologic symptoms should have CNS aspergillosis considered in their differential diagnosis.

1. Introduction

Invasive aspergillosis is common in immunocompromised patients with hematologic cancers (leukemia) and organ transplantation, and it has a very high mortality rate. Although uncommon in comparison to pulmonary aspergillosis, CNS aspergillosis is usually fatal if not treated promptly. They frequently occur within the brain parenchyma [4] or less frequently, in the ventricles [7,10].

Since the beginning of the ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19 infection has been shown to cause immune dysfunction or suppression, predisposing patients to bacterial and fungal co-infections [5,8]. Although, several cases of COVID-19 and invasive pulmonary aspergillosis (IPA) [5], and mucormycosis [8] have been reported, no case of COVID-19 and intraventricular aspergillosis (IVA) has been reported. We present a patient with a history of COVID-19 who was referred for IVA and pulmonary aspergillosis and discuss diagnosis and management of IVA. This is the first reported case, to the best of our knowledge.

Abbreviations: IVA, Intraventricular Aspergillosis; COVID-19, Coronavirus disease 2019; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; CNS, Central Nervous System; IPA, Invasive Pulmonary Aspergillosis; GCS, Glasgow Coma Scale.

* Corresponding author. Department of Neurosurgery, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

E-mail address: akhoshnevisan@tums.ac.ir (A. Khoshnevisan).

https://doi.org/10.1016/j.amsu.2022.104122
Received 9 June 2022; Received in revised form 29 June 2022; Accepted 1 July 2022
Available online 7 July 2022
2049-0801/© 2022 Published by Elsevier Ltd on behalf of LJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
2. Case presentation

A 58-year-old woman presented to the emergency department of our general hospital with a week of confusion, dysarthria, and stupor. The patient was hospitalized to the ICU ward and treated with corticosteroids among other medications for a serious COVID-19 infection she acquired a month earlier. Family and psychosocial history were negative. Physical examination revealed a patient who was ill, confused and disoriented, with a GCS of 9/15 (M5E2V2). A neurological examination left-sided hemiparesis and no papilledema. Motor examinations revealed that the upper and lower extremity muscle force of the left side were 2/5. Also, a positive plantar reflex was observed on the left foot. Her level of consciousness rapidly deteriorated a few hours after admission and neurosurgical consultation. The patient was immediately sent for a brain CT scan, which revealed a right hypodense intraventricular lesion with a midline shift. An MRI of the brain revealed a right intraventricular lesion that was isointense on T1&T2 weighted images. A large non-demarcated intraventricular lesion in the right lateral ventricle was observed, with perilesional edema, mass effect, and significant shift of the midline structures (Fig. 1).

The neurosurgeon (A.K) performed a posterior parietal craniotomy was on the patient. Following the opening of the dura, a transcortical approach from the posterior parietal region to the right lateral ventricle was made. The lateral ventricle’s ependymal layer was opened, and a soft, greyish-colored lesion with slight hemorrhage and local invasion into the ependyma was discovered. Using microscopic surgical techniques with suction and bipolar diathermy, a macroscopic gross total resection was performed. Histopathological examination revealed necrotic foci with numerous branching fungal hyphae with acute angle branching. This finding was consistent with a fungal infection caused by Aspergillus species (Fig. 2).

Fig. 1. Preoperative MRI image, A; T1W, Axial view. Isointense lesion in right ventricle with midline shift. B; PD MRI image, Axial view. Perilesional edema is seen. C; T2W image. Axial view: Isointense lesion in the right ventricle with surrounding edema and midline shift. (MRI, magnetic resonance imaging; PD, proton density).
3. Postoperative course

Following surgery, the patient’s condition and level of consciousness improved. Based on the histopathological reports, the patient was immediately started on intravenous (IV) amphotericin B 250 mg daily, which she received for two months before being switched to oral voriconazole 400 mg Bid for additional 4 months. Her postoperative recovery has been uneventful, and she has completely recovered from her symptoms. (Fig. 3A and B - depict post-op MRI images changes between 1 and 4 months). This case report has been reported in line with the SCARE Criteria [14].

4. Discussion

Patients with severe COVID-19 infection, like other immunocompromised patients, are susceptible to invasive fungal infection, including mucormycosis and aspergillosis [5,8]. SARS-CoV-2, the primary cause of COVID-19, uses a variety of mechanisms to compromise and suppress the immune system. It reduces T-lymphocytes and increase the production of interleukins (IL-1 and IL-6), which destabilizes the immune system and creates an environment conducive for secondary infection with Aspergillus species [13]. Also, SARS-CoV-2, via a SARS spike (S1) protein, binds to angiotensin-converting enzymes 2 (ACE2) receptors expressed on epithelial cells of pneumocytes and endothelial cells of blood vessels in brain, resulting in pulmonary infection and neurovascular damage, respectively [6,12]. Neurovascular inflammation...
Aspergillosis cases [4]. Notably, CNS aspergillosis has also been reported with septate hyphae of Aspergillus species [3]. Underlying conditions such as renal transplantation [7, 9], heroin abuse [9], schizophrenia [2] and acute lymphoblastic leukemia (ALL) [1] have been reported. In this case, the underlying condition was COVID-19 infection (with corticosteroid medication). In agreement with one author [13], we believe COVID-19 infection resulted in an immunocompromised state, which led to secondary infections of IPA and IVA. In four of the cases [1, 2, 7, 10], the isolated IVA lesion was found in the lateral ventricle. The rupture of an aspergillosis brain abscess affected the intraventricular space indirectly in one case [1]. Despite the fact that hydrocephalus was observed in 5 of the cases [2, 3, 7, 9, 10], our patient did not have it. In all cases, histological examination and culture were used to make the diagnosis. Only one case, however, specified the Aspergillus species involved [9]. Among the six previous cases, 4 died [2, 3, 7, 9, 10].

The prognosis of the CNS aspergillosis is generally abysmal. As a result, treatment should be aggressive and begin as soon as possible to improve patients’ chances of survival. Surgical excision and intravenous amphotericin B administration are common treatments for CNS aspergillosis (including IPA). For improved patient outcomes, additional treatment options such as intraventricular administration of amphotericin B have been described [11]. Despite the fact that, like other studies [2, 4], we attributed our patient’s survival to early surgical excision and the administration of antifungal agents. We also believe that COVID-19 infection causes less immunosuppression or immune dysfunction than.

Table 1
Clinical manifestation, management and prognosis of intraventricular aspergillosis.

| Cases/ (year) | Age/ Sex | Underlying condition | Symptom/ Physical finding | Location of infection | Location of cerebral lesion | Hydrocephalus | Treatment | Systemic fungal therapy | Duration of treatment | Outcome |
|---------------|----------|----------------------|---------------------------|----------------------|-----------------------------|--------------|----------|----------------------|----------------------|---------|
| Correa et al., /1975 [3] | 49/F | None | Headache; vomiting; Kernig \*/Brudzinski \*; Bilateral papilledema | Brain (intraventricular mass) | Fourth ventricle | Present | Craniotomy, Resection | None | – | Died after 1 week |
| Morrow et al., /1983 [5] | 36/M | Heroin abuser | Fever; Generalized seizures; Neck stiffness | Postmortem finding consistent with ventriculitis | Not specified | Present | No surgery | No Antifungal therapy | – | Died after 40 days |
| Chen et al., /2010 [2] | 39/M | Schizophrenia disease | Rapid decrease of LOC | Brain (intraventricular mass) | Right lateral ventricle | Present | Endoscopic ventriculostomy; Catheter drainage; VP shunt | Fluconazole; AmB, IV voriconazole (200 Bid)/ 2Week; Oral voriconazole (200 Bid)/ 2Week | 1 month | Alive at 12 month F/U |
| Larjani et al., /2019 [7] | 53/M | Renal transplantation | Rapid decrease of LOC, Bilateral papilledema | Brain (intraventricular mass) | Left lateral ventricle | Present | Endoscopic trans-middle frontal sulcus approach; Catheter drainage | No surgery | Not specified | – | Died after 3 day during hemodialysis |
| Adachi et al., /2020 [1] | 69/M | Acute lymphoblastic leukemia | Impaired LOC | Brain, multiple brain lesion; intraventricular brain abscess rupture | Right lateral ventricle | Absent | No surgery | L-AmB (5mg/kg/day); IV voriconazole (12mg/kg/ day) | Not specified | Died after 9 month with ALL relapse |
| Patel et al., /2020 [10] | 59/M | Renal transplantation | Right-sided weakness; Speech difficulty Fever; Confusion; Dysarthria; Rapid decrease of LOC; Babinski + | Lung (IPA); Brain (intraventricular mass) | Left lateral ventricle | Present | Catheter drainage; Surgical biopsy | Antifungal therapy not specified | Not specified | Not specified |
| Present cases/ 2022 | 58/F | COVID-19 infection; IPA | COVID-19 infection; IPA; | Lungs (IPA); Brain (intraventricular mass) | Right lateral ventricle | Absent | Craniotomy, Resection | IV AmB (3mg/kg/day) for 2 Months; Oral voriconazole 400 Bid (still on medication) | 7 months | Alive at 7 months F/U |

M, male; F, female; +, positive; -, not mentioned.

| Present cases/ 2022 | COVID-19 infection; IPA | Right-sided weakness; Speech difficulty Fever; Confusion; Dysarthria; Rapid decrease of LOC; Babinski + | Lung (IPA); Brain (intraventricular mass) | Right lateral ventricle | Absent | Craniotomy, Resection | IV AmB (3mg/kg/day) for 2 Months; Oral voriconazole 400 Bid (still on medication) | 7 months | Alive at 7 months F/U |

M, male; F, female; +, positive; -, not mentioned.
that seen in transplant patients or patients with hematologic malignancies who require immunosuppressive medications for a longer period of time to remain in remission. Furthermore, the ability to successfully treat patients with COVID-19, even in critical conditions, and the rapid evolution of vaccination are distinguishing features that distinguish patients with COVID-19 infection from other immunocompromised patients with CNS aspergillosis and/or IVA in terms of prognosis.

5. Conclusion

COVID-19 infection causes immune dysfunction, and it is possible to co-infect with bacterial and fungal agents, including Aspergillus species. As a result, in COVID-19 patients who exhibit confusion, loss of consciousness, seizures, or any neurological symptoms, aspergillosis should be considered in the differential diagnosis. Early administration of an antifungal agent such as amphotericin B may significantly improve patient outcome and prevent further neurologic deterioration and death.

Provenance and peer review

Not commissioned, externally peer reviewed.

Sources of funding

None.

Ethical approval

Not required.

Consent

Written Informed consent was obtained from the patient for publication of this case report and accompanying image. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author contributions

A.K, H.S: Conceived the idea.
S.B.K, M.S: Data collection, writing the paper.
A.K, S.B.K, S.A: Review and revised manuscript for intellectual content critically. All author approved the final version of the manuscript.

Registration of research studies

1. Name of the registry:
2. Unique Identifying number or registration ID:
3. Hyperlink to your specific registration (must be publicly accessible and will be checked):

Guarantor

Alireza Khoshnevisan.

Declaration of competing interest

None.

References

[1] H. Adachi, Y. Najima, T. Konishi, N. Sekiya, M. Hagihara, Intraventricular rupture of Aspergillus brain abscess during remission induction, Int. J. Infect. Dis. 101 (2020) 246–247. https://doi.org/10.1016/j.ijid.2020.10.016.
[2] D.C. Chen, T.H. Wu, S.C. Chen, B.T. Teo, P.S. Yen, Isolated intraventricular aspergillosis in a schizophrenic patient, J. Craniofac. Surg. 21 (2010) 1291–1294. https://doi.org/10.1097/SCS.0b013e3181e42245.
[3] A.J. Correa, R. Brinckhaus, S. Kesler, E. Martínez, Aspergillosis of the fourth ventricle: case report, J. Neurourosurg. 43 (1975) 236–238, https://doi.org/10.3171/jns.1975.43.2.0236.
[4] N.E. Epstein, R. Hollingsworth, K. Black, P. Farmer, Fungal brain abscesses (aspergillosis/mucormycosis) in two immunosuppressed patients, Surg. Neurol. 35 (1991) 286–289, https://doi.org/10.1016/0090-3019(91)90006-U.
[5] P. Koehler, O.A. Cornely, B.W. Böttger, F. Dunse, D.A. Elchenauer, F. Fuchs, et al., COVID-19 associated pulmonary aspergillosis, Mycoses 63 (2020) 528–534, https://doi.org/10.1111/mmc.13096.
[6] K. Kuba, Y. Imai, S. Rao, H. Gao, F. Guo, B. Guan, et al., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury, Nat. Med. 11 (2005) 875–879, https://doi.org/10.1038/nm1267.
[7] Larijani A, Darvishi A, Karimi-Yarandi K, Ahmadi SA, Alimohamadi M. Acute Hydrocephalus Due to Intraventricular CNS Aspergillosis: A Case Report. Acta Med. Iran. :461-32019. https://doi.org/10.18502/acta.v57i7.2335.
[8] I. Mahalaxmi, K. Jayaramayya, D. Venkatesan, M.D. Subramaniam, K. Renu, P. Vijayakumar, et al., Mucormycosis: an opportunistic pathogen during COVID-19, Environ. Res. 201 (2021), 111643, https://doi.org/10.1016/j.envres.2021.111643.
[9] R. Morrow, B. Wong, W.E. Finkelstein, S.S. Sternberg, D. Armstrong, Aspergillosis of the cerebral ventricles in a heroin abuser: case report and review of the literature, Arch. Intern. Med. 143 (1983) 161–164, https://doi.org/10.1001/archmed.1983.0090032.00064.
[10] P.Y. Patel, S.C. Patel, D. Noujaim, J. Corrigan, B. Griffith, Ventricular Entrapment Due to Isolated Intraventricular Aspergillus Infection, 2020. https://scholarlycommons.henryford.com/merf2020caserept/37/.
[11] A.P. Schausvlieghoeve, R.G. Bredius, R.M. Verdijk, F.J. Smiers, M.T. van der Beek, B. F. Goemans, et al., Management of cerebral azole-resistant Aspergillus fumigatus infection: a role for intraventricular liposomal-amphotericin B, J. Glob. Antimicrob. Resist. 22 (2020) 354–357, https://doi.org/10.1016/j.jgar.2020.03.016.
[12] A. Sepehrinezhad, A. Shahbazi, S.S. Negah, COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective review, J. Neurovirol. 26 (2020) 324–329, https://doi.org/10.1007/s13365-020-00851-2.
[13] X. Zhang, Y. Tan, Y. Líng, G. Lu, F. Liu, Z. Yi, et al., Viral and host factors related to the clinical outcome of COVID-19, Nature 583 (2020) 437–440, https://doi.org/10.1038/s41586-020-2305-0.
[14] R.A. Agha, T. Franchi, C. Soltrabi, G. Mathew, for the SCARE Group, The SCARE 2020 guideline: Guideline: updating Consensus on Surgical Case Report (SCARE) guidelines, Int. J. Surg. 84 (2020) 226–230.